Compare TG Therapeutics Inc (TGTX) vs Vanguard Information Technology Index Fund ETF (VGT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Vanguard Information Technology Index Fund ETF — how do they compare? TG Therapeutics Inc trades at $55.37 (market cap $8.16B), while Vanguard Information Technology Index Fund ETF trades at $127.98 (market cap $170.20B). The key difference: Vanguard Information Technology Index Fund ETF is far larger — about 20.9× TG Therapeutics Inc's market cap, and Vanguard Information Technology Index Fund ETF is more actively traded (5,132,883 versus 1,735,121). Which is the better fit depends on your goals — on Pluang, investors hold TG Therapeutics Inc for 16 Days and Vanguard Information Technology Index Fund ETF for 129 Days on average.
| TGTX | VGT | |
|---|---|---|
Market Cap | $8.16B | $170.20B |
Volume | 1,735,121 | 5,132,883 |
Sector | Health | — |
52-Week High | $59.06 | $129.79 |
52-Week Low | $26.94 | $83.59 |
Typical Hold Time | 16 Days | 129 Days |
Enterprise Value | $8.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.
The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.
VGT trades at $127.25, down 1.64% on the day but maintains a bullish technical outlook with strong moving average support. The ETF's concentration in leading technology companies like Nvidia, Apple, and Microsoft provides exposure to AI and cloud computing growth trends. Recent articles highlight VGT's historical performance of over 17% annual returns over the past two decades.
The outlook remains positive given technology sector momentum and VGT's low expense ratio advantage. Key risks include sector concentration and potential AI market slowdowns. Current technical positioning near pivot point resistance at $128 suggests potential for breakout if momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Vanguard Information Technology Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the MSCI US Investable Market Index/Information Technology 25/50, an index made up of stocks of large, mid-size, and small US companies within the information technology sector, as classified under the GICS. The advisor attempts to replicate the target index by seeking to invest all of its assets in the stocks that make up the index, in order to hold each stock in approximately the same proportion as its weighting in the index. It is non-diversified.
Read more on VGT →
